Plain-English translation of NCT05285358 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new approach called pressurized intraperitoneal aerosolized chemotherapy (PIPAC) using combined with two standard chemotherapy drugs: and . The study focuses on patients with bile duct or gallbladder cancer that has spread to the lining of the abdomen. Researchers want to see if delivering one medication directly into the abdominal cavity while also giving standard chemotherapy through the veins can be done safely and help patients live longer.
When bile duct or gallbladder cancer spreads to the abdominal lining, it is very difficult to treat and patients have few options. This trial exists to explore whether this new delivery method—spraying medication directly where the cancer has spread—might work better than standard treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive treatment in repeating 3-week cycles for up to 8 cycles total. On days 1 and 8 of each cycle, you'd receive two standard chemotherapy drugs through an IV ( and ). On day 3 of cycles 1, 3, and 5, you would have the new medication delivered directly into your abdomen during a brief procedure. You would be followed closely with blood tests, imaging scans, and check-ins with your doctor, plus you would complete quality-of-life questionnaires and wear a step counter to track your activity.
AI-generated summary from trial data · Sep 6, 2026 · Not medical advice
United States